Board Of Directors

Committees:

• Audit
• ESG

Attributes and skills:

• Experience in investment business
• Experience in healthcare industry
• Public-company director experience
• Experience in fundamental valuation and corporate management analysis
• Experience in Environmental, Social and Governance (ESG) initiatives

Expertise provided to the Board:

Edward P. Bousa has over 37 years of experience in the investment business and spent over 20 years at Wellington Management Company LLP where he was a Partner and Team Lead of Quality Value Investment Strategies and helped grow that team’s assets under management to over $90 billion. Mr. Bousa also has deep experience in the healthcare industry providing an investor-focused approach to the healthcare delivery market. He possesses significant experience in fundamental valuation and corporate management analysis, having executed over 7,000 in depth assessments of company management teams. Mr. Bousa is also a proven advocate of ESG initiatives, having led broad firm participation in ESG engagements at Wellington.

Committees:

• Audit
• Nominating and Governance

Attributes and skills:

• Global business experience
• Financial management and accounting
• Audit
• Risk management and investment stewardship experience
• Financing transactions
• Mergers & acquisitions / integrations
• Experience in highly regulated industries
• Leadership and talent development

Expertise provided to the Board:

Following forty years at KPMG in various roles, including as Vice Chair of Audit, Frank E. Casal brings best-in-class knowledge of financial reporting, accounting and audit, drawing on his experience providing supervisory responsibilities to large, global Fortune 500 companies. To the Azenta Board, he brings significant expertise in transforming businesses through mergers and acquisitions, financing transactions and other strategic priorities, including Azenta’s split from Brooks Automation. Having led a division of almost 9,000 professionals, he has proven leadership and management experience. He provides a unique perspective to the Board as it manages talent and human capital to support efforts to grow the Company and generate shareholder value.

Committees:

• Human Resources and Compensation (Chair)
• Finance

Attributes and skills:

• Leadership experience in life sciences and healthcare companies
• Risk management and investment stewardship experience
• Operational experience in capital-intensive, innovation-focused industries
• Growth strategies and market expansion
• Mergers & acquisitions / integrations
• Leadership and talent development

Expertise provided to the Board:

As a Managing Director at an early-stage angel investment group focused on medical devices, life sciences and pharmaceutical companies, Robyn C. Davis brings a valuable investor perspective geared towards maximizing value for shareholders. She also possesses strong financial acumen, particularly as it relates to operational matters, and experience supporting companies as they scale and grow, both organically and through mergers and acquisitions, having successfully exited certain portfolio companies and sat on the Board of CRA Health during its acquisition by Volpara. She brought her experience in operations, growth and life sciences to the Board as Azenta transitioned from Brooks Automation into a standalone global market leader. She has more than three decades of independent C-suite consulting experience with both corporate and non-governmental organizations helping to lead value-creation strategies in growth, cost reduction, leadership and talent development.

Committees:

• Audit (Chair)
• Finance

Attributes and skills:

• Executive leadership experience at healthcare and life sciences companies
• Public-company director experience
• Global business experience
• Risk management and investment stewardship
• Growth strategies and market expansion
• Experience in highly regulated industries

Expertise provided to the Board:

Didier Hirsch brings deep financial and industry experience as a former public company CFO at Agilent Technologies, Inc., a global leader in life science, diagnostic and applied technical markets. Mr. Hirsch also has significant financial and risk management expertise, having served on the Board of four other public companies, including as chair of the audit committee. He also possesses substantial international experience and regulatory knowledge from previous work in the technology and semiconductor sectors.

Committees:

• Human Resources and Compensation
• Nominating and Governance

Attributes and skills:

• Executive leadership experience at healthcare and life sciences companies
• Public-company director experience
• Global business experience
• Mergers & acquisitions/integrations
• Growth strategies and market expansion
• Experience in highly regulated industries

Expertise provided to the Board:

Martin D. Madaus is an experienced public company CEO who has spent his career in diagnostics and life science tools, both as an executive and a board member. Dr. Madaus has a proven track record of creating shareholder value in public and private life science companies. He has notable experience in strategy, mergers and acquisitions and commercial transformations. Dr. Madaus led the sale of Millipore Corporation to Merck KGaA for $7.2 billion and led the $4.2 billion leveraged buy-out of Ortho Clinical Diagnostics.

Mr. Marotta joined Azenta Life Sciences in September 2024 as President and CEO. He has two decades of experience leading global companies in life sciences, medical devices, and diagnostics.

Prior to joining the company, Mr. Marotta served as Executive in Residence of Patient Square Capital, a leading healthcare investment firm. Previously, he served as CEO and President of PHC Holdings Corporation (formerly Panasonic Health Care), a diversified global life sciences, diagnostics, and medical device company focused on precision healthcare, growing global revenues, and leading its IPO from owners KKR Capital. He also held a variety of senior executive roles in leading life sciences companies, including Danaher, Envista Holdings, and Cardinal Health, where he demonstrated consistent achievement in organic revenue growth, operational efficiencies, and significant value-creating transactions. Mr. Marotta began his career in sales leadership roles for therapeutics and medical device offerings.

Mr. Marotta received his BS from the University of Dayton and his MBA from the University of Denver, Daniels School of Business.

Committees:

• Nomination and Governance (Chair)
• Audit

Attributes and skills:

• Global business experience
• Financial management and accounting
• Audit
• Growth strategies and market expansion
• ESG
• Mergers & acquisitions / integrations
• Leadership and talent development

Expertise provided to the Board:

As a results-driven Executive Vice President, CFO and Head of Corporate Strategy of a public company, Erica J. McLaughlin brings extensive international business experience and expertise in financial areas and strategy and a strong background in accounting and audit. She also has significant experience in mergers, acquisitions and integrations, as well as industrial knowledge of life sciences, having served on Azenta’s Board during its Company’s transition from Brooks Automation. With proven general management and leadership experience at global organizations, she has her finger on the pulse of best-practice corporate governance and sustainable growth strategies. Further, her experience both as the Inaugural Chairperson of Cabot’s Diversity and Inclusion Steering Committee and as Co-Chair of the Governance pillar at Cabot’s ESG executive management structure, means that she brings valuable insights relating to ESG, DEI and other matters top-of-mind for leadership.

Committees:

• Finance (Chair)
• ESG

Attributes and skills:

• Leadership experience in life sciences and healthcare companies
• Global business experience
• Growth strategies and market expansion
• Public-company director experience
• Mergers & acquisitions / integrations
• Operational experience in capital-intensive, innovation-focused industries
• Experience in highly regulated industries

Expertise provided to the Board:

Tina S. Nova is an industry veteran in life sciences, with deep experience in building and leading businesses in the industry, providing deep insights into best-in-class operations, sales and marketing efforts. She also brings significant experience in mergers, acquisitions and integration, having overseen the sale of several companies as both an executive and director that created value for shareholders. She also provides relevant life sciences executive leadership experience, having held Chief Executive roles at Decipher Biosciences, until its $600 million sale to Veracyte in 2021, Molecular Stethoscope and Genoptix, which she co-founded and oversaw its $470 million sale to Novartis AG in 2011.

Committees:

• ESG (Chair)
• Human Resources and Compensation

Attributes and skills:

• Leadership experience in life sciences and healthcare companies
• Global business experience
• Risk management and investment stewardship
• Growth strategies and market expansion
• Experience in highly regulated industries

Expertise provided to the Board:

Michael Rosenblatt, MD has deep leadership and executive experience in the biotechnology industry, including as the chief medical officer of a major pharmaceutical company and at a substantial life sciences investment firm. He also has deep board-level and management team experience as a founding scientist, scientific advisory Board member, director of more than a dozen biopharmaceutical companies and Board member during the Company’s transition from Brooks Automation to Azenta Life Sciences. Further, thanks to his academic leadership experience as a dean and professor at prestigious medical schools and as a leader in the biotech industry, including as a winner of the Fuller Albright Award, he has extensive expertise in drug discovery and medical research, bringing unique industry insights to the Azenta Board, particularly as it relates to the customer perspective, research and development, as well as opportunities in the marketplace.

Committees:

• Audit
• ESG

Attributes and skills:

• Experience in investment business
• Experience in healthcare industry
• Public-company director experience
• Experience in fundamental valuation and corporate management analysis
• Experience in Environmental, Social and Governance (ESG) initiatives

Expertise provided to the Board:

Edward P. Bousa has over 37 years of experience in the investment business and spent over 20 years at Wellington Management Company LLP where he was a Partner and Team Lead of Quality Value Investment Strategies and helped grow that team’s assets under management to over $90 billion. Mr. Bousa also has deep experience in the healthcare industry providing an investor-focused approach to the healthcare delivery market. He possesses significant experience in fundamental valuation and corporate management analysis, having executed over 7,000 in depth assessments of company management teams. Mr. Bousa is also a proven advocate of ESG initiatives, having led broad firm participation in ESG engagements at Wellington.

Committees:

• Audit
• Nominating and Governance

Attributes and skills:

• Global business experience
• Financial management and accounting
• Audit
• Risk management and investment stewardship experience
• Financing transactions
• Mergers & acquisitions / integrations
• Experience in highly regulated industries
• Leadership and talent development

Expertise provided to the Board:

Following forty years at KPMG in various roles, including as Vice Chair of Audit, Frank E. Casal brings best-in-class knowledge of financial reporting, accounting and audit, drawing on his experience providing supervisory responsibilities to large, global Fortune 500 companies. To the Azenta Board, he brings significant expertise in transforming businesses through mergers and acquisitions, financing transactions and other strategic priorities, including Azenta’s split from Brooks Automation. Having led a division of almost 9,000 professionals, he has proven leadership and management experience. He provides a unique perspective to the Board as it manages talent and human capital to support efforts to grow the Company and generate shareholder value.

Committees:

• Human Resources and Compensation (Chair)
• Finance

Attributes and skills:

• Leadership experience in life sciences and healthcare companies
• Risk management and investment stewardship experience
• Operational experience in capital-intensive, innovation-focused industries
• Growth strategies and market expansion
• Mergers & acquisitions / integrations
• Leadership and talent development

Expertise provided to the Board:

As a Managing Director at an early-stage angel investment group focused on medical devices, life sciences and pharmaceutical companies, Robyn C. Davis brings a valuable investor perspective geared towards maximizing value for shareholders. She also possesses strong financial acumen, particularly as it relates to operational matters, and experience supporting companies as they scale and grow, both organically and through mergers and acquisitions, having successfully exited certain portfolio companies and sat on the Board of CRA Health during its acquisition by Volpara. She brought her experience in operations, growth and life sciences to the Board as Azenta transitioned from Brooks Automation into a standalone global market leader. She has more than three decades of independent C-suite consulting experience with both corporate and non-governmental organizations helping to lead value-creation strategies in growth, cost reduction, leadership and talent development.

Committees:

• Audit (Chair)
• Finance

Attributes and skills:

• Executive leadership experience at healthcare and life sciences companies
• Public-company director experience
• Global business experience
• Risk management and investment stewardship
• Growth strategies and market expansion
• Experience in highly regulated industries

Expertise provided to the Board:

Didier Hirsch brings deep financial and industry experience as a former public company CFO at Agilent Technologies, Inc., a global leader in life science, diagnostic and applied technical markets. Mr. Hirsch also has significant financial and risk management expertise, having served on the Board of four other public companies, including as chair of the audit committee. He also possesses substantial international experience and regulatory knowledge from previous work in the technology and semiconductor sectors.

Committees:

• Human Resources and Compensation
• Nominating and Governance

Attributes and skills:

• Executive leadership experience at healthcare and life sciences companies
• Public-company director experience
• Global business experience
• Mergers & acquisitions/integrations
• Growth strategies and market expansion
• Experience in highly regulated industries

Expertise provided to the Board:

Martin D. Madaus is an experienced public company CEO who has spent his career in diagnostics and life science tools, both as an executive and a board member. Dr. Madaus has a proven track record of creating shareholder value in public and private life science companies. He has notable experience in strategy, mergers and acquisitions and commercial transformations. Dr. Madaus led the sale of Millipore Corporation to Merck KGaA for $7.2 billion and led the $4.2 billion leveraged buy-out of Ortho Clinical Diagnostics.

Mr. Marotta joined Azenta Life Sciences in September 2024 as President and CEO. He has two decades of experience leading global companies in life sciences, medical devices, and diagnostics.

Prior to joining the company, Mr. Marotta served as Executive in Residence of Patient Square Capital, a leading healthcare investment firm. Previously, he served as CEO and President of PHC Holdings Corporation (formerly Panasonic Health Care), a diversified global life sciences, diagnostics, and medical device company focused on precision healthcare, growing global revenues, and leading its IPO from owners KKR Capital. He also held a variety of senior executive roles in leading life sciences companies, including Danaher, Envista Holdings, and Cardinal Health, where he demonstrated consistent achievement in organic revenue growth, operational efficiencies, and significant value-creating transactions. Mr. Marotta began his career in sales leadership roles for therapeutics and medical device offerings.

Mr. Marotta received his BS from the University of Dayton and his MBA from the University of Denver, Daniels School of Business.

Committees:

• Nomination and Governance (Chair)
• Audit

Attributes and skills:

• Global business experience
• Financial management and accounting
• Audit
• Growth strategies and market expansion
• ESG
• Mergers & acquisitions / integrations
• Leadership and talent development

Expertise provided to the Board:

As a results-driven Executive Vice President, CFO and Head of Corporate Strategy of a public company, Erica J. McLaughlin brings extensive international business experience and expertise in financial areas and strategy and a strong background in accounting and audit. She also has significant experience in mergers, acquisitions and integrations, as well as industrial knowledge of life sciences, having served on Azenta’s Board during its Company’s transition from Brooks Automation. With proven general management and leadership experience at global organizations, she has her finger on the pulse of best-practice corporate governance and sustainable growth strategies. Further, her experience both as the Inaugural Chairperson of Cabot’s Diversity and Inclusion Steering Committee and as Co-Chair of the Governance pillar at Cabot’s ESG executive management structure, means that she brings valuable insights relating to ESG, DEI and other matters top-of-mind for leadership.

Committees:

• Finance (Chair)
• ESG

Attributes and skills:

• Leadership experience in life sciences and healthcare companies
• Global business experience
• Growth strategies and market expansion
• Public-company director experience
• Mergers & acquisitions / integrations
• Operational experience in capital-intensive, innovation-focused industries
• Experience in highly regulated industries

Expertise provided to the Board:

Tina S. Nova is an industry veteran in life sciences, with deep experience in building and leading businesses in the industry, providing deep insights into best-in-class operations, sales and marketing efforts. She also brings significant experience in mergers, acquisitions and integration, having overseen the sale of several companies as both an executive and director that created value for shareholders. She also provides relevant life sciences executive leadership experience, having held Chief Executive roles at Decipher Biosciences, until its $600 million sale to Veracyte in 2021, Molecular Stethoscope and Genoptix, which she co-founded and oversaw its $470 million sale to Novartis AG in 2011.

Committees:

• ESG (Chair)
• Human Resources and Compensation

Attributes and skills:

• Leadership experience in life sciences and healthcare companies
• Global business experience
• Risk management and investment stewardship
• Growth strategies and market expansion
• Experience in highly regulated industries

Expertise provided to the Board:

Michael Rosenblatt, MD has deep leadership and executive experience in the biotechnology industry, including as the chief medical officer of a major pharmaceutical company and at a substantial life sciences investment firm. He also has deep board-level and management team experience as a founding scientist, scientific advisory Board member, director of more than a dozen biopharmaceutical companies and Board member during the Company’s transition from Brooks Automation to Azenta Life Sciences. Further, thanks to his academic leadership experience as a dean and professor at prestigious medical schools and as a leader in the biotech industry, including as a winner of the Fuller Albright Award, he has extensive expertise in drug discovery and medical research, bringing unique industry insights to the Azenta Board, particularly as it relates to the customer perspective, research and development, as well as opportunities in the marketplace.